Immunotherapeutic Strategies for Alpha-Synuclein Pathology in Neurodegenerative Disorders

Immunotherapeutic approaches targeting alpha-synuclein pathology aim to modify the course of synucleinopathies by harnessing the host immune system or delivering exogenous antibodies to neutralise toxic forms of the protein. Strategies include passive immunisation with monoclonal antibodies that recognise aggregated or oligomeric alpha-synuclein species, active vaccination to elicit a sustained endogenous antibody response, and epitope-mimicking vaccines that selectively present conformational determinants of pathogenic assemblies. These interventions seek to reduce extracellular propagation, enhance microglial clearance, preserve synaptic function and delay neurodegeneration across disorders such as Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy. Advances in structural biology, biomarker development and patient stratification are driving a precision-medicine paradigm. Challenges remain in overcoming the blood–brain barrier, minimising off-target immune activation and identifying early-stage cohorts most likely to benefit. The global significance of these strategies lies in their potential to transform treatment from symptomatic management to disease modification.

Research from Nature Portfolio

Recent studies have advanced our understanding of disease-modifying potential of anti-α-synuclein antibodies. A 2024 phase 2 trial of prasinezumab, a humanised monoclonal antibody targeting aggregated α-synuclein, demonstrated slower progression of motor symptoms in subgroups with rapidly progressing early Parkinson’s disease, notably diffuse malignant phenotypes and those on MAO-B inhibitors at baseline. Although the primary clinical endpoint was not met, exploratory analyses suggest enhanced benefits in well-defined patient subsets, underscoring the importance of precision stratification and adaptive trial design for future immunotherapeutic interventions.

Immunotherapeutic Strategies for Alpha-Synuclein Pathology in Neurodegenerative Disorders publication trend

The graph below shows the total number of articles in immunotherapeutic strategies for alpha-synuclein pathology in neurodegenerative disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Alpha-synuclein: A neuronal protein prone to misfolding and aggregation into toxic oligomers and fibrils, central to synucleinopathy pathogenesis.

Monoclonal antibody: A uniform immunoglobulin molecule engineered to bind a single specific epitope on a target antigen such as aggregated alpha-synuclein.

Passive immunisation: Administration of exogenous antibodies to confer immediate, short-term immunity or neutralisation of a pathogenic agent.

Active immunisation: Vaccination that stimulates the host’s own immune system to produce antibodies and memory cells against a specific antigen.

Conformational epitope: A three-dimensional determinant formed by non-contiguous amino acid residues in a protein’s folded structure, often unique to pathogenic aggregates.

References

1. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease. Nature Medicine (2024).
2. Vaccination with structurally adapted fungal protein fibrils induces immunity to Parkinson’s disease. Brain (2024).
3. Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054. Movement Disorders (2019).